[DOI] [PMC free article] [PubMed] [Google Scholar] 27.Reiter C, Weinshilboum RM
OptumRx, February 2026 prior authorization criteria update Wegovy is FDA-approved for chronic weight management (BMI 30+, or 27+ with a weight-related comorbidity) and for cardiovascular risk reduction in adults with established CVD it is a weight-loss and CV drug, not a diabetes drug
These effects are short-lived and typically stop occurring as the individual becomes adept at self-administering the injections
The first noticeable effect is usually a decrease in appetite and an increased feeling of fullness, which helps patients adhere better to their dietary plans and achieve compounding benefits
The cumulative effect of sustained appetite suppression and improved metabolic function leads to the substantial health improvements reported in clinical literature
GHK-Cu (Copper Peptide): Known for its exceptional skin-regenerating properties, GHK-Cu stimulates collagen and elastin synthesis